The tumor suppressor TERE1 (UBIAD1) prenyltransferase regulates the elevated cholesterol phenotype in castration resistant prostate cancer by controlling a program of ligand dependent SXR target genes

Oncotarget

Volumn 4, Issue 7, 2013, Pages 1075-1092

  Fredericks, William J ^a   Sepulveda, Jorge ^b   Lal, Priti ^c   Tomaszewski, John E ^d   Lin, Ming Fong ^e   McGarvey, Terry ^f   Rauscher III, Frank J ^g   Malkowicz, S Bruce ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b New York Presbyterian Columbia University Medical Center   (United States)

^c HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY AT BUFFALO   (United States)

^e UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^f A T STILL UNIVERSITY   (United States)

^g WISTAR INSTITUTE   (United States)

Author keywords

Androgen catabolism; Castrate resistant prostate cancer; Cholesterol; CRPC; LnCaP; Prostate cancer; SXR; TERE1; UBIAD1; Vitamin K 2

Indexed keywords

ABC TRANSPORTER G1; ANDROGEN RECEPTOR; APOLIPOPROTEIN E; CD36 ANTIGEN; CELL NUCLEUS RECEPTOR; CHOLESTEROL; CHOLESTEROL 7ALPHA MONOOXYGENASE; DIMETHYLALLYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 2B7; LIVER RECEPTOR HOMOLOG 1; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; NUCLEAR RECEPTOR SXR; TERE1 PROTEIN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CASTRATION RESISTANT PROSTATE CANCER; CHOLESTEROL SYNTHESIS; CHOLESTEROL TRANSPORT; ENZYME SYNTHESIS; GENE CONTROL; GENE TARGETING; HUMAN; IMMUNOHISTOCHEMISTRY; MICROARRAY ANALYSIS; PHENOTYPE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR GROWTH;

CELL LINE, TUMOR; CHOLESTEROL; DIMETHYLALLYLTRANSTRANSFERASE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIGANDS; MALE; PHENOTYPE; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RECEPTORS, STEROID; TRANSFECTION; VITAMIN K;

EID: 84884259809     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1103     Document Type: Article

References (89)

1. Shen MM and Abate-Shen C. Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev. 2010; 24(18):1967-2000.
2. Pelton K, Freeman MR and Solomon KR. Cholesterol and prostate cancer. Curr Opin Pharmacol. 2012; 12(6):751-759.
3. Parnes HL, House MG and Tangrea JA. Prostate cancer prevention: strategies for agent development. Curr Opin Oncol. 2013; 25(3):242-251.
4. Azzouni F and Mohler J. Biology of castration-recurrent prostate cancer. Urol Clin North Am. 2012; 39(4):435-452.
5. Locke JA, Wasan KM, Nelson CC, Guns ES and Leon CG. Androgen-mediated cholesterol metabolism in LNCaP and PC-3 cell lines is regulated through two different isoforms of acyl-coenzyme A:Cholesterol Acyltransferase (ACAT). Prostate. 2008; 68(1):20-33.
6. Leon CG, Locke JA, Adomat HH, Etinger SL, Twiddy AL, Neumann RD, Nelson CC, Guns ES and Wasan KM. Alterations in cholesterol regulation contribute to the production of intratumoral androgens during progression to castration-resistant prostate cancer in a mouse xenograft model. Prostate. 2010; 70(4):390-400.
7. Dillard PR, Lin MF and Khan SA. Androgen-independent prostate cancer cells acquire the complete steroidogenic potential of synthesizing testosterone from cholesterol. Mol Cell Endocrinol. 2008; 295(1-2):115-120.
8. Krycer JR, Kristiana I and Brown AJ. Cholesterol homeostasis in two commonly used human prostate cancer cell-lines, LNCaP and PC-3. PLoS One. 2009; 4(12):e8496.
9. Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano CS, True LD and Nelson PS. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res. 2008; 68(11):4447-4454.
10. Mostaghel EA, Page ST, Lin DW, Fazli L, Coleman IM, True LD, Knudsen B, Hess DL, Nelson CC, Matsumoto AM, Bremner WJ, Gleave ME and Nelson PS. Intraprostatic Androgens and Androgen-Regulated Gene Expression Persist after Testosterone Suppression: Therapeutic Implications for Castration-Resistant Prostate Cancer. Cancer Research. 2007; 67(10):5033-5041.
11. Nelson PS. Molecular states underlying androgen receptor activation: a framework for therapeutics targeting androgen signaling in prostate cancer. J Clin Oncol. 2012; 30(6):644-646.
12. Freeman MR and Solomon KR. Cholesterol and prostate cancer. J Cell Biochem. 2004; 91(1):54-69.
13. Zhuang L, Kim J, Adam RM, Solomon KR and Freeman MR. Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. J Clin Invest. 2005; 115(4):959-968.
14. Zhuang L, Lin J, Lu ML, Solomon KR and Freeman MR. Cholesterol-rich lipid rafts mediate akt-regulated survival in prostate cancer cells. Cancer Res. 2002; 62(8):2227-2231.
15. Li YC, Park MJ, Ye SK, Kim CW and Kim YN. Elevated levels of cholesterol-rich lipid rafts in cancer cells are correlated with apoptosis sensitivity induced by cholesterol-depleting agents. Am J Pathol. 2006; 168(4):1107-1118; quiz 1404-1105.
16. Martinez-Abundis E, Garcia N, Correa F, Franco M and Zazueta C. Changes in specific lipids regulate BAX-induced mitochondrial permeability transition. Febs J. 2007; 274(24):6500-6510.
17. Oh HY, Lee EJ, Yoon S, Chung BH, Cho KS and Hong SJ. Cholesterol level of lipid raft microdomains regulates apoptotic cell death in prostate cancer cells through EGFR-mediated Akt and ERK signal transduction. Prostate. 2007; 67(10):1061-1069.
18. Li CG, Gruidl M, Eschrich S, McCarthy S, Wang HG, Alexandrow MG and Yeatman TJ. Insig2 is associated with colon tumorigenesis and inhibits Bax-mediated apoptosis. Int J Cancer. 2008; 123(2):273-282.
19. Christenson E, Merlin S, Saito M and Schlesinger P. Cholesterol effects on BAX pore activation. J Mol Biol. 2008; 381(5):1168-1183.
20. Decker KF, Zheng D, He Y, Bowman T, Edwards JR and Jia L. Persistent androgen receptor-mediated transcription in castration-resistant prostate cancer under androgen-deprived conditions. Nucleic Acids Res. 2012; 40(21):10765-10779.
21. Goldstein JL, DeBose-Boyd RA and Brown MS. Protein sensors for membrane sterols. Cell. 2006; 124(1):35-46.
22. Makishima M. Nuclear receptors as targets for drug development: regulation of cholesterol and bile acid metabolism by nuclear receptors. J Pharmacol Sci. 2005; 97(2):177-183.
23. Wang Y, Rogers PM, Su C, Varga G, Stayrook KR and Burris TP. Regulation of cholesterologenesis by the oxysterol receptor, LXRalpha. J Biol Chem. 2008; 283(39):26332-26339.
24. Blumberg B, Sabbagh W, Jr., Juguilon H, Bolado J, Jr., van Meter CM, Ong ES and Evans RM. SXR, a novel steroid and xenobiotic-sensing nuclear receptor. Genes Dev. 1998; 12(20):3195-3205.
25. Zhou C, King N, Chen KY and Breslow JL. Activation of PXR induces hypercholesterolemia in wild-type and accelerates atherosclerosis in apoE deficient mice. J Lipid Res. 2009; 50(10):2004-2013.
26. Tall AR. Cholesterol efflux pathways and other potential mechanisms involved in the athero-protective effect of high density lipoproteins. J Intern Med. 2008; 263(3):256-273.
27. Zhou X, Yin Z, Guo X, Hajjar DP and Han J. Inhibition of ERK1/2 and activation of liver X receptor synergistically induce macrophage ABCA1 expression and cholesterol efflux. J Biol Chem. 2010; 285(9):6316-6326.
28. Singh AP, Bafna S, Chaudhary K, Venkatraman G, Smith L, Eudy JD, Johansson SL, Lin MF and Batra SK. Genome-wide expression profiling reveals transcriptomic variation and perturbed gene networks in androgen-dependent and androgen-independent prostate cancer cells. Cancer Lett. 2008; 259(1):28-38.
29. McGarvey TW, Nguyen T, Tomaszewski JE, Monson FC and Malkowicz SB. Isolation and characterization of the TERE1 gene, a gene down-regulated in transitional cell carcinoma of the bladder. Oncogene. 2001; 20(9):1042-1051.
30. McGarvey TW, Nguyen T, Puthiyaveettil R, Tomaszewski JE and Malkowicz SB. TERE1, a novel gene affecting growth regulation in prostate carcinoma. Prostate. 2003; 54(2):144-155.
31. Nickerson ML, Kostiha BN, Brandt W, Fredericks W, Xu KP, Yu FS, Gold B, Chodosh J, Goldberg M, Lu da W, Yamada M, Tervo TM, Grutzmacher R, Croasdale C, Hoeltzenbein M, Sutphin J, et al. UBIAD1 mutation alters a mitochondrial prenyltransferase to cause Schnyder corneal dystrophy. PLoS ONE. 2010; 5(5):e10760.
32. Fredericks WJ, McGarvey T, Wang H, Lal P, Puthiyaveettil R, Tomaszewski J, Sepulveda J, Labelle E, Weiss JS, Nickerson ML, Kruth HS, Brandt W, Wessjohann LA and Malkowicz SB. The bladder tumor suppressor protein TERE1 (UBIAD1) modulates cell cholesterol: implications for tumor progression. DNA Cell Biol. 2011; 30(11):851-864.
33. Fredericks WJ, McGarvey T, Wang H, Zheng Y, Fredericks NJ, Yin H, Wang LP, Hsiao W, Lee R, Weiss JS, Nickerson ML, Kruth HS, Rauscher FJ, 3rd and Malkowicz SB. The TERE1 (UBIAD1) bladder tumor suppressor protein interacts with mitochondrial TBL2: regulation of trans-membrane potential, oxidative stress and SXR signaling to the nucleus. J Cell Biochem. 2013 Apr 8. doi: 10.1002/jcb.24567. [Epub ahead of print] PMID: 23564352
34. Nickerson ML, Bosley AD, Weiss JS, Kostiha BN, Hirota Y, Brandt W, Esposito D, Kinoshita S, Wessjohann L, Morham SG, Andresson T, Kruth HS, Okano T and Dean M. The UBIAD1 prenyltransferase links menaquione-4 synthesis to cholesterol metabolic enzymes. Hum Mutat. 2013; 34(2):317-329.
35. Weiss JS, Kruth HS, Kuivaniemi H, Tromp G, White PS, Winters RS, Lisch W, Henn W, Denninger E, Krause M, Wasson P, Ebenezer N, Mahurkar S and Nickerson ML. Mutations in the UBIAD1 gene on chromosome short arm 1, region 36, cause Schnyder crystalline corneal dystrophy. Invest Ophthalmol Vis Sci. 2007; 48(11):5007-5012.
36. Nakagawa K, Hirota Y, Sawada N, Yuge N, Watanabe M, Uchino Y, Okuda N, Shimomura Y, Suhara Y and Okano T. Identification of UBIAD1 as a novel human menaquinone-4 biosynthetic enzyme. Nature. 2010; 468(7320):117-21.
37. Lamson DW and Plaza SM. The anticancer effects of vitamin K. Altern Med Rev. 2003; 8(3):303-318.
38. Nishikawa Y, Wang Z, Kerns J, Wilcox CS and Carr BI. Inhibition of hepatoma cell growth in vitro by arylating and non-arylating K vitamin analogs. Significance of protein tyrosine phosphatase inhibition. J Biol Chem. 1999; 274(49):34803-34810.
39. Gilloteaux J, Jamison JM, Neal DR, Loukas M, Doberzstyn T and Summers JL. Cell damage and death by autoschizis in human bladder (RT4) carcinoma cells resulting from treatment with ascorbate and menadione. Ultrastruct Pathol. 2010; 34(3):140-160.
40. Vos M, Esposito G, Edirisinghe JN, Vilain S, Haddad DM, Slabbaert JR, Van Meensel S, Schaap O, De Strooper B, Meganathan R, Morais VA and Verstreken P. Vitamin K2 is a mitochondrial electron carrier that rescues pink1 deficiency. Science. 2012; 336(6086):1306-1310.
41. Nowicka B and Kruk J. Occurrence, biosynthesis and function of isoprenoid quinones. Biochim Biophys Acta. 2010; 1797(9):1587-1605.
42. Tielens AG, Rotte C, van Hellemond JJ and Martin W. Mitochondria as we don't know them. Trends Biochem Sci. 2002; 27(11):564-572.
43. Ihunnah CA, Jiang M and Xie W. Nuclear receptor PXR, transcriptional circuits and metabolic relevance. Biochim Biophys Acta. 2011; 1812(8):956-963.
44. Zhou C, Verma S and Blumberg B. The steroid and xenobiotic receptor (SXR), beyond xenobiotic metabolism. Nucl Recept Signal. 2009; 7:e001.
45. Tabb MM, Sun A, Zhou C, Grun F, Errandi J, Romero K, Pham H, Inoue S, Mallick S, Lin M, Forman BM and Blumberg B. Vitamin K2 regulation of bone homeostasis is mediated by the steroid and xenobiotic receptor SXR. J Biol Chem. 2003; 278(45):43919-43927.
46. Shearer MJ and Newman P. Metabolism and cell biology of vitamin K. Thromb Haemost. 2008; 100(4):530-547.
47. Zhang B, Cheng Q, Ou Z, Lee JH, Xu M, Kochhar U, Ren S, Huang M, Pflug BR and Xie W. Pregnane X Receptor As a Therapeutic Target to Inhibit Androgen Activity. Endocrinology. 2010; 151(12): 5721-9
48. Amundson DM and Zhou M. Fluorometric method for the enzymatic determination of cholesterol. J Biochem Biophys Methods. 1999; 38(1):43-52.
49. Fredericks WJ, Yin H, Lal P, Puthiyaveettil R, Malkowicz SB, Tomaszewski J, Fredericks NJ, Rauscher FJI and Malkowicz SB. Ectopic expression of the TERE1 (UBIAD1) protein inhibits growth of Renal Clear Cell Carcinoma cells: Altered metabolic phenotype associated with reactive oxygen species, nitric oxide, and SXR target genes involved in cholesterol and lipid metabolism. Int J Oncol. 2013; 43(2): 638-52. doi: 10.3892/ijo.2013.1985. [Epub ahead of print] PMID: 23759948
50. Wang TT. Large-Scale in Silico and Microarray-Based Identification of Direct 1,25-Dihydroxyvitamin D3 Target Genes. Molecular Endocrinology. 2005; 19(11):2685-2695.
51. Stewart LV, Lyles B, Lin MF and Weigel NL. Vitamin D receptor agonists induce prostatic acid phosphatase to reduce cell growth and HER-2 signaling in LNCaP-derived human prostate cancer cells. J Steroid Biochem Mol Biol. 2005; 97(1-2):37-46.
52. Krishnan AV, Shinghal R, Raghavachari N, Brooks JD, Peehl DM and Feldman D. Analysis of vitamin D-regulated gene expression in LNCaP human prostate cancer cells using cDNA microarrays. The Prostate. 2004; 59(3):243-251.
53. Landes N. Homologous metabolic and gene activating routes for vitamins E and K. Molecular Aspects of Medicine. 2003; 24(6):337-344.
54. Lim YP and Huang JD. Interplay of pregnane X receptor with other nuclear receptors on gene regulation. Drug Metab Pharmacokinet. 2008; 23(1):14-21.
55. Brown AJ and Jessup W. Oxysterols: Sources, cellular storage and metabolism, and new insights into their roles in cholesterol homeostasis. Molecular Aspects of Medicine. 2009; 30(3):111-122.
56. Sonoda J, Chong LW, Downes M, Barish GD, Coulter S, Liddle C, Lee CH and Evans RM. Pregnane X receptor prevents hepatorenal toxicity from cholesterol metabolites. Proc Natl Acad Sci U S A. 2005; 102(6):2198-2203.
57. Wang X and Rader DJ. Molecular regulation of macrophage reverse cholesterol transport. Curr Opin Cardiol. 2007; 22(4):368-372.
58. Wang X, Collins HL, Ranalletta M, Fuki IV, Billheimer JT, Rothblat GH, Tall AR and Rader DJ. Macrophage ABCA1 and ABCG1, but not SR-BI, promote macrophage reverse cholesterol transport in vivo. J Clin Invest. 2007; 117(8):2216-2224.
59. Patra SK. Dissecting lipid raft facilitated cell signaling pathways in cancer. Biochim Biophys Acta. 2008; 1785(2):182-206.
60. Swinnen JV, Brusselmans K and Verhoeven G. Increased lipogenesis in cancer cells: new players, novel targets. Curr Opin Clin Nutr Metab Care. 2006; 9(4):358-365.
61. Shen MM and Abate-Shen C. Pten Inactivation and the Emergence of Androgen-Independent Prostate Cancer. Cancer Research. 2007; 67(14):6535-6538.
62. Adam RM, Mukhopadhyay NK, Kim J, Di Vizio D, Cinar B, Boucher K, Solomon KR and Freeman MR. Cholesterol sensitivity of endogenous and myristoylated Akt. Cancer Res. 2007; 67(13):6238-6246.
63. Montero J, Morales A, Llacuna L, Lluis JM, Terrones O, Basanez G, Antonsson B, Prieto J, Garcia-Ruiz C, Colell A and Fernandez-Checa JC. Mitochondrial cholesterol contributes to chemotherapy resistance in hepatocellular carcinoma. Cancer Res. 2008; 68(13):5246-5256.
64. Di Vizio D, Solomon KR and Freeman MR. Cholesterol and cholesterol-rich membranes in prostate cancer: an update. Tumori. 2008; 94(5):633-639.
65. Twiddy AL, Leon CG and Wasan KM. Cholesterol as a Potential Target for Castration-Resistant Prostate Cancer. Pharm Res. 2010; 28, 423-437.
66. McGarvey TW, Nguyen TB and Malkowicz SB. An interaction between apolipoprotein E and TERE1 with a possible association with bladder tumor formation. J Cell Biochem. 2005; 95(2):419-428.
67. Matic M, Mahns A, Tsoli M, Corradin A, Polly P and Robertson GR. Pregnane X receptor: promiscuous regulator of detoxification pathways. Int J Biochem Cell Biol. 2007; 39(3):478-483.
68. Suhara Y, Watanabe M, Motoyoshi S, Nakagawa K, Wada A, Takeda K, Takahashi K, Tokiwa H and Okano T. Synthesis of new vitamin K analogues as steroid and xenobiotic receptor (SXR) agonists: insights into the biological role of the side chain part of vitamin K. J Med Chem. 2011; 54(13):4918-4922.
69. Suhara Y, Watanabe M, Nakagawa K, Wada A, Ito Y, Takeda K, Takahashi K and Okano T. Synthesis of novel vitamin K2 analogues with modification at the omega-terminal position and their biological evaluation as potent steroid and xenobiotic receptor (SXR) agonists. J Med Chem. 2011; 54(12):4269-4273.
70. Nimptsch K, Rohrmann S, Kaaks R and Linseisen J. Dietary vitamin K intake in relation to cancer incidence and mortality: results from the Heidelberg cohort of the European Prospective Investigation into Cancer and Nutrition (EPIC-Heidelberg). Am J Clin Nutr. 2010; 91(5):1348-1358.
71. Lee BH, Taylor MG, Robinet P, Smith JD, Schweitzer J, Sehayek E, Falzarano SM, Magi-Galluzzi C, Klein EA and Ting AH. Dysregulation of cholesterol homeostasis in human prostate cancer through loss of ABCA1. Cancer Res. 2013; 73(3):1211-1218.
72. Aouabdi S, Gibson G and Plant N. Transcriptional regulation of the PXR gene: identification and characterization of a functional peroxisome proliferator-activated receptor alpha binding site within the proximal promoter of PXR. Drug Metab Dispos. 2006; 34(1):138-144.
73. Ichikawa T. Steroid and Xenobiotic Receptor SXR Mediates Vitamin K2-activated Transcription of Extracellular Matrix-related Genes and Collagen Accumulation in Osteoblastic Cells. Journal of Biological Chemistry. 2006; 281(25):16927-16934.
74. Horie-Inoue K and Inoue S. Steroid and xenobiotic receptor mediates a novel vitamin K2 signaling pathway in osteoblastic cells. Journal of Bone and Mineral Metabolism. 2008; 26(1):9-12.
75. Nagaoka R, Iwasaki T, Rokutanda N, Takeshita A, Koibuchi Y, Horiguchi J, Shimokawa N, Iino Y, Morishita Y and Koibuchi N. Tamoxifen activates CYP3A4 and MDR1 genes through steroid and xenobiotic receptor in breast cancer cells. Endocrine. 2006; 30(3):261-268.
76. Verma S, Tabb MM and Blumberg B. Activation of the steroid and xenobiotic receptor, SXR, induces apoptosis in breast cancer cells. BMC Cancer. 2009; 9:3.
77. Trasino SE, Kim YS and Wang TT. Ligand, receptor, and cell type-dependent regulation of ABCA1 and ABCG1 mRNA in prostate cancer epithelial cells. Mol Cancer Ther. 2009; 8(7):1934-1945.
78. Chuu CP, Hiipakka RA, Kokontis JM, Fukuchi J, Chen RY and Liao S. Inhibition of tumor growth and progression of LNCaP prostate cancer cells in athymic mice by androgen and liver X receptor agonist. Cancer Res. 2006; 66(13):6482-6486.
79. Skowronski RJ, Peehl DM and Feldman D. Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. Endocrinology. 1993; 132(5):1952-1960.
80. Gupta AK, Sexton RC and Rudney H. Effect of vitamin D3 derivatives on cholesterol synthesis and HMG-CoA reductase activity in cultured cells. J Lipid Res. 1989; 30(3):379-386.
81. Swami S, Krishnan AV and Feldman D. Vitamin D metabolism and action in the prostate: implications for health and disease. Mol Cell Endocrinol. 2011; 347(1-2):61-69.
82. Echchgadda I, Song CS, Roy AK and Chatterjee B. Dehydroepiandrosterone sulfotransferase is a target for transcriptional induction by the vitamin D receptor. Mol Pharmacol. 2004; 65(3):720-729.
83. Gimenez-Bonafe P, Fedoruk MN, Whitmore TG, Akbari M, Ralph JL, Ettinger S, Gleave ME and Nelson CC. YB-1 is upregulated during prostate cancer tumor progression and increases P-glycoprotein activity. Prostate. 2004; 59(3):337-349.
84. Penning TM and Byrns MC. Steroid Hormone Transforming Aldo-Keto Reductases and Cancer. Annals of the New York Academy of Sciences. 2009; 1155(1):33-42.
85. Byrns MC and Penning TM. Type 5 17beta-hydroxysteroid dehydrogenase/prostaglandin F synthase (AKR1C3): role in breast cancer and inhibition by non-steroidal anti-inflammatory drug analogs. Chem Biol Interact. 2009; 178(1-3):221-227.
86. Wang J-H and Tuohimaa P. Regulation of 17ß-hydroxysteroid dehydrogenase type 2, type 4 and type 5 by calcitriol, LXR agonist and 5a-dihydrotestosterone in human prostate cancer cells. The Journal of Steroid Biochemistry and Molecular Biology. 2007; 107(1-2):100-105.
87. Barbier O and Belanger A. Inactivation of androgens by UDP-glucuronosyltransferases in the human prostate. Best Pract Res Clin Endocrinol Metab. 2008; 22(2):259-270.
88. Kumar S, Jaiswal B, Negi S and Tyagi RK. Cross-talk between androgen receptor and pregnane and xenobiotic receptor reveals existence of a novel modulatory action of anti-androgenic drugs. Biochem Pharmacol. 2010; 80(7):964-976.
89. Lindenthal B, Aldaghlas TA, Holleran AL, Sudhop T, Berthold HK, Von Bergmann K and Kelleher JK. Isotopomer spectral analysis of intermediates of cholesterol synthesis in human subjects and hepatic cells. Am J Physiol Endocrinol Metab. 2002; 282(6):E1222-1230.